NCT03605680View on ClinicalTrials.gov

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

604

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

April 11, 2020

Study Completion Date

April 11, 2020

Conditions

Attention Deficit DisorderAttention Deficit Hyperactivity Disorder

Interventions

DRUG

Centanafadine SR

100 mg, BID, oral tablets

OTHER

Placebo

BID, oral tablet.

DRUG

Centanafadine SR

200 mg, BID, oral tablets

Trial Locations (1)

10022

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03605680 - A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter